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 Mounting evidence suggests that cancer development is due to a rare population of cancer 
stem cells (CSC) uniquely able to initiate and sustain the disease (Al-Hajj et al., 2003; Bonnet and 
Dick, 1997; Lapidot et al., 1994; Li and Ren, 2008; Singh et al., 2003; Smalley and Ashworth, 
2003).  Conventional chemotherapeutics which inhibit cell proliferation are however ineffective 
against quiescent CSCs capable of re-initiating the disease (Bao et al., 2006; Dean et al., 2005; 
Diehn et al., 2009; Diehn and Clarke, 2006; Eyler and Rich, 2008; Li et al., 2008; Woodward et 
al., 2007).  Instead, the indiscriminate cytotoxicity of these drugs often affects normal stem cells 
and progenitor populations, leading to dosage restrictions and necessitating supportive treatment 
(Smith et al., 2006).  This traditional therapy has defined current patient survival rates, but these 
rates remain largely unchanged during the past 3 decades (Estey and Dohner, 2006; Visvader 
and Lindeman, 2008) implying that novel approaches are required to fight cancer.  Recently, 
agents that selectively induce CSC apoptosis have been identified (Gupta et al., 2009) but their 
impact on normal stem cells has yet to be validated.  
 Stem cells, whether normal or CSC, are defined by an equilibrium between 1) self-renewal 
and 2) differentiation.  In the case of CSCs, this equilibrium shifts towards enhanced self-renewal 
and limited differentiation capacity.  A deviation in equilibrium however leads to eventual stem cell 
exhaustion (Duncan et al., 2005). One approach to eradicate CSCs is to tilt the equilibrium in 
favour of terminal differentiation in an effort to exhaust the CSC population. Eliminating cancer by 
inducing differentiation was first proposed in the 1970s (Fibach et al., 1973; Friend et al., 1971; 
Sachs, 1978a; Sachs, 1978b).  This led to the identification of all-trans-retinoic acid (ATRA) 
(Breitman et al., 1981; Breitman et al., 1980) and then arsenic trioxide (ATO) (Niu et al., 1999; 
Raffoux et al., 2003) as differentiation-inducing agents for the treatment of acute promyelocytic 
leukemia (APL), an acute myeloid leukemia (AML) subtype.  If left untreateted, APL causes death 
within weeks.  ATRA/ATO treatment of APL currently demonstrates remission rates in excess of 
93% with 5-year overall patient survival rates approaching 100% (Sanz, 2006; Sanz et al., 2009; 
Wang and Chen, 2008) and exemplifies how differentiation therapy can be used to transformed 
a fatal, non-resectable, cancer to one that is essentially curable.     
Cancer differentiation therapy has not however been translated to the treatment of other 
cancer types, let alone other AML subtypes (Burnett et al., 2010; Estey et al., 1999). This failure 
is, in part, due to the absence of robust in vitro assays which can interrogate CSC differentiation.    
To address these issues, an overview of the application of automation for cancer stem cell 
screening will be presented.  
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